Gabriele Fendrich

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Molecular Pharmacology, Mutant Bcr-abl, Medicine +5

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 590 citations

Molecular Pharmacology, Drug Target, Medicine +5

The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation

Sandra W. Cowan‐Jacob, Gabriele Fendrich, Paul W. Manley et al. · Structure · 2005 · 341 citations · Full text

Crystal Structure, Biochemistry, C-src Activation +8

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Sandra W. Cowan‐Jacob, Gabriele Fendrich, Andreas Floersheimer et al. · Acta Crystallographica Section D Biological Crystallography · 2006 · 282 citations · Full text

Imatinib-resistant Patients, Mutant Abl Kinase, Hematological Malignancy +12

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Paul W. Manley, Peter Drueckes, Gabriele Fendrich et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2009 · 218 citations

Drug Target, Medicine, Receptor Tyrosine Kinase +8